New Drug Cures 20% of Hepatitis B Patients in Trial

For the first time, scientists have found a way to functionally cure chronic hepatitis B, a viral infection that leads to liver cancer and has stumped researchers for decades.

A new drug called bepirovirsen cured 20% of patients in a global study of more than 1,800 people across 29 countries. The virus remained undetectable in their bodies 48 weeks after treatment ended, according to results published in the New England Journal of Medicine.

"The results are remarkable," said Dr. Anna S. Lok, assistant dean for clinical research at the University of Michigan Medical School. She called the success "a major step forward."

Hepatitis B is the world's most common liver infection and the leading cause of liver cancer. About 296 million people live with the chronic form of the disease, which develops when the immune system fails to clear the virus naturally.

Current treatments require patients to take antivirals and immune-boosting medications for life. These drugs don't eliminate the virus or remove the risk of liver cancer, leaving patients with a lifelong burden.

Bepirovirsen works differently. Developed by Ionis Pharmaceuticals and GlaxoSmithKline, the weekly injection prevents the virus from replicating and helps the immune system attack it effectively.

In the study, none of the patients who received the placebo were cured. The trial excluded people with cirrhosis, HIV, or very high hepatitis B levels, meaning more research is needed to understand how the drug works in these groups.

The virus spreads through contact with infected blood or body fluids, typically during childbirth, sex, or needle sharing. While 95% of adults clear acute infections on their own, those who don't face serious long-term health risks.

The Bright Side

This breakthrough arrives at a crucial moment. In 2023 alone, the U.S. saw 17,650 new chronic hepatitis B cases and 1,769 related deaths.

The hepatitis B vaccine, which has been protecting 98% of healthy infants since 1991, shows that prevention works. Now, for the 296 million people already living with chronic infection, this new treatment offers something that didn't exist before: a realistic path to being virus-free.

One in five patients experiencing a functional cure might not sound like complete victory, but for a disease that was entirely incurable just months ago, it represents genuine medical progress. As researchers continue refining the treatment and studying it in more diverse patient groups, that percentage could grow.

After decades of dead ends, people with chronic hepatitis B finally have reason to hope.